NCM
SCMP

Nantahala Capital Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Nantahala Capital Management’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-320,466
Closed -$2.11M – 90
2013
Q2 		$2.11M Buy
+320,466
New +$2.54M 0.49% 55

Other funds holding SCMP

GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nantahala Capital Management's SCMP Position: Q3 2013 in Review

Nantahala Capital Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q3 2013, closing a stake of 320,466 shares — an estimated $2.11M sold.

Nantahala Capital Management first reported a position in SCMP in Q2 2013 and held it in 1 quarter. The position peaked at $2.11M in Q2 2013. 69 funds tracked by Wall St. Rank hold SCMP as of Q3 2013.

  • Nantahala Capital Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q3 2013 after selling out during the quarter.
  • Nantahala Capital Management sold 320,466 Sucampo Pharmaceuticals, Inc. shares in Q3 2013, an estimated $2.11M.
  • Nantahala Capital Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 1 quarter.
  • Nantahala Capital Management's Sucampo Pharmaceuticals, Inc. position peaked at $2.11M in Q2 2013.
  • 69 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q3 2013.

Based on Nantahala Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.